共 50 条
- [41] Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme JOURNAL OF CROHNS & COLITIS, 2020, 14 : S460 - S461
- [42] Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis JOURNAL OF CROHNS & COLITIS, 2021, 15 (10): : 1774 - 1774
- [43] Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S377 - S377
- [44] Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme JOURNAL OF CROHNS & COLITIS, 2023, 17 (11): : 1761 - 1770
- [48] Tofacitinib Adherence and Outcomes in Patients With Refractory Ulcerative Colitis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S411 - S411
- [49] Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis Clinical Drug Investigation, 2024, 44 : 285 - 288